A late relapse thymoma and pure red cell aplasia case with an over 5 years of clinical response under everolimus

KÖKSOY E. B., AKBULUT H.

ANTI-CANCER DRUGS, cilt.34, sa.10, ss.1193-1195, 2023 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34 Sayı: 10
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1097/cad.0000000000001504
  • Dergi Adı: ANTI-CANCER DRUGS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.1193-1195
  • Anahtar Kelimeler: everolimus, long-term clinical benefit, thymoma, THYMIC CARCINOMA, PHASE-II, CHEMOTHERAPY, MALIGNANCIES, ONCOLOGY
  • Ankara Üniversitesi Adresli: Evet

Özet

Although several agents showed some clinical activity in patients with recurrent thymoma, there is no standard treatment option. Here, we report a late relapse thymoma and pure red cell aplasia case, responsive to everolimus with over 5 years of clinical benefit following multiple lines of treatment. Everolimus controlled the rapidly progressive disease in our patient without significant toxicity.